| Identification | Back Directory | [Name]
DEOXYACTEIN, 27-(23-EPI-26-DEOXYACTEIN)(RG) | [CAS]
501938-01-8 | [Synonyms]
DEOXYACTEIN, 27-(23-EPI-26-DEOXYACTEIN)(RG)
β-D-Xylopyranoside, (3β,12β,16β,23R,24R,25R)-12-(acetyloxy)-16,23:23,26:24,25-triepoxy-9,19-cyclolanostan-3-yl | [Molecular Formula]
C37H56O10 | [MDL Number]
MFCD07783721 | [MOL File]
501938-01-8.mol | [Molecular Weight]
660.85 |
| Chemical Properties | Back Directory | [density ]
1.32±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [form ]
Solid | [pka]
13.03±0.70(Predicted) | [color ]
White to off-white | [Major Application]
pharmaceutical | [InChIKey]
GCMGJWLOGKSUGX-UHFFFAOYSA-N | [SMILES]
O1C(C(C(C(C1)O)O)O)OC2C(C3C4(C5(C(C6(C(C7C(OC8(OCC9(OC98)C)CC7C)C6)(C(C5)OC(=O)C)C)C)CC3)C4)CC2)(C)C |
| Hazard Information | Back Directory | [Uses]
pharmaceutical | [Definition]
ChEBI: 23-epi-26-deoxyactein is a triterpenoid. It has a role as a metabolite. | [in vivo]
23-epi-26-Deoxyactein (DA: 5 and 10 mg/kg/d) significantly lowers body weight gain, fat mass, and liver weight in HFD-fed mice. 23-epi-26-Deoxyactein (DA) also reduces insulin resistance and serum lipoprotein levels in HFD-fed mice[1].
23-epi-26-Deoxyactein (DA) promotes adipocyte lipolysis in mice through activating the AMPK signaling and SIRT1-FOXO1 pathway[1].
| Animal Model: | Diet induced obesity in C57BL/6 mice[1]. | | Dosage: | 1-10 mg/kg. | | Administration: | Orally, daily for 12 weeks. | | Result: | Lowered body weight gain, fat mass, and liver weight.
5 mg/kg/d DA significantly improved HFD-induced glucose intolerance.
|
|
|
| Company Name: |
TargetMol
|
| Telephone: |
400-821-0310 15002144251 |
| Website: |
www.targetmol.cn/ |
|